about
Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNAPresence of Cx43 in extracellular vesicles reduces the cardiotoxicity of the anti-tumour therapeutic approach with doxorubicinMolecular cloning and analysis of SSc5D, a new member of the scavenger receptor cysteine-rich superfamily.Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours.Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer.Genetic screening for familial gastric cancer.Loss and recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions.E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer.Germline mutations in MAP3K6 are associated with familial gastric cancerDifferent types of epithelial cadherin alterations play different roles in human carcinogenesis.Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. an interplay with E-cadherin.Biological properties of extracellular vesicles and their physiological functions.Finding and tracing human MSC in 3D microenvironments with the photoconvertible protein Dendra2Helicobacter pylori chronic infection and mucosal inflammation switches the human gastric glycosylation pathwaysGenetics, pathology, and clinics of familial gastric cancer.CDX2 regulation by the RNA-binding protein MEX3A: impact on intestinal differentiation and stemness.Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer.Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer.Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC)Germline CDH1 deletions in hereditary diffuse gastric cancer familiesMolecular targets and biological modifiers in gastric cancer.Hereditary gastric cancer.KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers.E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer.Epithelial E- and P-cadherins: role and clinical significance in cancer.Colorectal cancer and RASSF family--a special emphasis on RASSF1A.E-cadherin dysfunction in gastric cancer--cellular consequences, clinical applications and open questions.Cancer syndromes and therapy by stop-codon readthrough.E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer.Gastric cancer: adding glycosylation to the equation.Therapeutic targets associated to E-cadherin dysfunction in gastric cancer.Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.Hereditary diffuse gastric cancer - pathophysiology and clinical management.Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer.Extracellular Vesicles - Powerful Markers of Cancer EVolution.Familial gastric cancer: genetic susceptibility, pathology, and implications for management.Hereditary cancer risk assessment: challenges for the next-gen sequencing era.Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer.Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
P50
Q24320146-5BF51CB2-CDFA-445D-B14C-C91CA0D0AA82Q30817598-31D1CE89-8D74-4A90-AFC8-FE85F3B32027Q33470094-F662BFE0-0365-46E3-B0DF-D3FA28713F64Q33594249-6A494FB2-50E2-4669-AE49-13450D56BDD1Q33630653-C0EFAC4F-9856-4A69-81CA-1AC5D419710CQ33732282-9C5D1918-EB6C-4790-8644-B996246A7308Q34200620-D60A9559-6D14-45BC-B8B2-411F2AD386DFQ34217518-7CA13D34-D167-4ABF-BDA9-969F599F731DQ34394597-AF900A7E-DC93-4020-A468-1B01C40F5597Q34985210-EC99DB71-01AC-4DFD-A669-465D476DDB5CQ35055368-3EA15505-BA62-47BB-9809-DA07C50D717DQ35611763-66DD8B77-D58C-484F-BBB7-C8963D27B93AQ35631589-11F7B01E-C851-453C-B7F1-CB64908F1D68Q36263451-7C0CE1B5-C41D-4BD6-82CA-DF4973535A69Q36406529-EF1CC712-3F98-4926-9D5D-BC26AB61828CQ36769451-204661EC-EC3F-4D08-BBFB-45817004C745Q36826934-67323589-859E-42CD-A02D-A35BD27A284EQ36930288-9F8BB010-5D80-442E-9319-FE15D802C1BBQ37043791-E0C14674-3E19-4F2E-9E84-6508A7C67B49Q37154264-25417630-9B6F-4DB9-B8D4-D1B8C2E46379Q37327351-E0AADA70-D3DF-4337-8E40-18A11F45BF22Q37469480-69EA9503-044A-4E02-9182-102AAE57CD6EQ37808800-72212754-7EE6-4F6E-84B5-504017D4F110Q37812175-9A55C4F4-40D7-4CD0-A67C-E9B26984F8A4Q38011915-D0C05832-6AE8-4F89-BC56-49D7F85020F5Q38021701-0F58A657-CBDC-4504-B40A-E759A4445537Q38030236-D4ED2C9A-018E-467A-B030-F8FA98C16FF8Q38050262-C64546B7-9CCC-41D8-8764-BCBD798C7853Q38088484-D71D80B9-62DC-40EB-8F88-DF200B87E3DCQ38128077-C58995FE-5079-4D2A-A062-B14392065340Q38129925-D240674A-FB6E-49C5-8096-5571282BB577Q38184380-FAACC9D8-151F-411F-97C6-0CCB6D7A84C9Q38260444-4FC4422C-78FF-45E6-8FED-B72681A60A2AQ38273497-0B589867-A753-4091-84CD-BC613B943E0EQ38326633-46BBBC66-2D4D-41DA-97AF-8A73CD669190Q38335195-B9589B9D-081C-4207-8FAA-4B2E1268BB74Q38339098-E675BF36-A43F-433C-8DD2-93CFD438CA32Q38411228-9B6B2F38-D484-40EF-8DC3-6E9BF2338495Q38425012-0E76411C-C1C6-4482-B60B-1C4FD6C18706Q38475420-A372ACDE-4C97-4639-80BF-FD09D6D77534
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carla Oliveira
@ast
Carla Oliveira
@en
Carla Oliveira
@es
Carla Oliveira
@nl
Carla Oliveira
@sl
type
label
Carla Oliveira
@ast
Carla Oliveira
@en
Carla Oliveira
@es
Carla Oliveira
@nl
Carla Oliveira
@sl
prefLabel
Carla Oliveira
@ast
Carla Oliveira
@en
Carla Oliveira
@es
Carla Oliveira
@nl
Carla Oliveira
@sl
P106
P1153
7102223149
P21
P31
P496
0000-0001-8340-2264